Role of Chemoimmunotherapy in Frontline Treatment of mUC
March 19th 2021Petros Grivas, MD, PhD, discusses the role of concurrent immune checkpoint inhibition plus chemotherapy in first-line metastatic urothelial carcinoma and comments on the ongoing phase 3 NILE, CheckMate 901, and EV-3O2 studies.
Read More